ADPT Adaptive Biotechnologies Corp

Price (delayed)

$2.44

Market cap

$354.03M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.56

Enterprise value

$515.46M

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the ...

Highlights
ADPT's equity is down by 34% year-on-year and by 15% since the previous quarter
The gross profit has declined by 26% year-on-year and by 12% since the previous quarter

Key stats

What are the main financial stats of ADPT
Market
Shares outstanding
145.09M
Market cap
$354.03M
Enterprise value
$515.46M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.15
Price to sales (P/S)
2.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.03
Earnings
Revenue
$170.28M
EBIT
-$211.45M
EBITDA
-$182.3M
Free cash flow
-$167.02M
Per share
EPS
-$1.56
Free cash flow per share
-$1.16
Book value per share
$2.13
Revenue per share
$1.18
TBVPS
$3.72
Balance sheet
Total assets
$661.13M
Total liabilities
$352.86M
Debt
$229.43M
Equity
$308.4M
Working capital
$322.17M
Liquidity
Debt to equity
0.74
Current ratio
4.66
Quick ratio
4.4
Net debt/EBITDA
-0.89
Margins
EBITDA margin
-107.1%
Gross margin
55.6%
Net margin
-132.3%
Operating margin
-133.3%
Efficiency
Return on assets
-30.7%
Return on equity
-60.5%
Return on invested capital
-32.2%
Return on capital employed
-36.9%
Return on sales
-124.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADPT stock price

How has the Adaptive Biotechnologies stock price performed over time
Intraday
1.67%
1 week
-16.15%
1 month
-24.69%
1 year
-71.59%
YTD
-50.2%
QTD
-23.99%

Financial performance

How have Adaptive Biotechnologies's revenue and profit performed over time
Revenue
$170.28M
Gross profit
$94.72M
Operating income
-$227.04M
Net income
-$225.25M
Gross margin
55.6%
Net margin
-132.3%
The gross profit has declined by 26% year-on-year and by 12% since the previous quarter
Adaptive Biotechnologies's operating margin has decreased by 23% YoY and by 23% QoQ
ADPT's net margin is down by 23% year-on-year and by 21% since the previous quarter
The gross margin has declined by 19% year-on-year and by 7% since the previous quarter

Growth

What is Adaptive Biotechnologies's growth rate over time

Valuation

What is Adaptive Biotechnologies stock price valuation
P/E
N/A
P/B
1.15
P/S
2.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.03
ADPT's EPS is down by 15% since the previous quarter and by 11% year-on-year
ADPT's P/B is 80% below its 5-year quarterly average of 5.6 and 55% below its last 4 quarters average of 2.5
ADPT's equity is down by 34% year-on-year and by 15% since the previous quarter
ADPT's price to sales (P/S) is 93% lower than its 5-year quarterly average of 28.3 and 60% lower than its last 4 quarters average of 5.1
The revenue has contracted by 8% YoY and by 5% from the previous quarter

Efficiency

How efficient is Adaptive Biotechnologies business performance
The ROE has shrunk by 53% YoY and by 27% QoQ
Adaptive Biotechnologies's ROA has decreased by 31% YoY and by 23% from the previous quarter
ADPT's return on sales is down by 23% since the previous quarter and by 18% year-on-year
The ROIC has contracted by 23% from the previous quarter and by 8% YoY

Dividends

What is ADPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADPT.

Financial health

How did Adaptive Biotechnologies financials performed over time
The total assets is 87% more than the total liabilities
The total assets has contracted by 23% YoY and by 8% from the previous quarter
The quick ratio has declined by 11% year-on-year
ADPT's debt is 26% smaller than its equity
ADPT's debt to equity is up by 48% year-on-year and by 16% since the previous quarter
ADPT's equity is down by 34% year-on-year and by 15% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.